GAMMA Investing LLC Grows Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

GAMMA Investing LLC increased its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 66.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,963 shares of the company’s stock after purchasing an additional 786 shares during the quarter. GAMMA Investing LLC’s holdings in Inari Medical were worth $100,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in NARI. KBC Group NV increased its holdings in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Inari Medical in the 2nd quarter valued at approximately $104,000. Quest Partners LLC increased its holdings in Inari Medical by 31,257.1% in the 2nd quarter. Quest Partners LLC now owns 2,195 shares of the company’s stock valued at $106,000 after purchasing an additional 2,188 shares during the last quarter. Finally, Covestor Ltd increased its holdings in Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after purchasing an additional 926 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Piper Sandler boosted their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective for the company. Baird R W cut shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Truist Financial lifted their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Inari Medical in a research report on Tuesday. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Inari Medical currently has a consensus rating of “Hold” and a consensus price target of $68.00.

Insiders Place Their Bets

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00. Following the transaction, the director now directly owns 561,233 shares in the company, valued at approximately $28,089,711.65. This trade represents a 6.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 406,000 shares of company stock valued at $22,621,870 in the last ninety days. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Trading Down 0.0 %

NARI opened at $79.29 on Friday. The company has a fifty day simple moving average of $54.11 and a 200 day simple moving average of $49.35. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of -58.73 and a beta of 0.97. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $79.69.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.